Preoperative Stereotactic Body Radiation Therapy for Soft-Tissue Sarcoma: Results of Phase 2 Study

Gregory J Kubicek; Tae Won Kim; Christina J Gutowski; Maureen Kaden; Gary Eastwick; Polina Khrizman; Qianyi Xu; Richard Lackman

doi:10.1016/j.adro.2021.100855

Preoperative Stereotactic Body Radiation Therapy for Soft-Tissue Sarcoma: Results of Phase 2 Study

Adv Radiat Oncol. 2021 Nov 20;7(2):100855. doi: 10.1016/j.adro.2021.100855. eCollection 2022 Mar-Apr.

Authors

Gregory J Kubicek¹, Tae Won Kim², Christina J Gutowski², Maureen Kaden², Gary Eastwick¹, Polina Khrizman³, Qianyi Xu¹, Richard Lackman²

Affiliations

¹ Department of Radiation Oncology, Cooper University Hospital, Camden, New Jersey.
² Department of Orthopedic Surgery, Cooper University Hospital, Camden, New Jersey.
³ Department of Medical Oncology, Cooper University Hospital, Camden, New Jersey.

Abstract

Purpose: Preoperative radiation followed by surgical resection is a standard treatment for soft-tissue sarcomas (STS). We report on 2 consecutive, phase 2, single-arm studies evaluating 5 fraction stereotactic body radiation therapy (SBRT) treatments followed by surgical resection for STS (clinical trails.gov NCT02706171).

Methods and materials: A total of 16 patients were treated with preoperative SBRT. Tumor size in the greatest dimension was a median 6.7 cm (maximum: 14 cm) and the majority of STS were in the extremities. SBRT consisted of 35 to 40 Gy in 5 fractions every other day.

Results: Median follow-up time was 1719 days (4.7 years). Grade ≥3 acute toxicity occurred in 1 patient (grade 3 skin changes). Fifteen patients proceeded with surgical resection. Three patients had a wound complication after surgery, 1 patient had grade ≥3 late toxicity (grade 4 requiring surgical intervention). There was 1 local recurrence and 5 distant recurrences.

Conclusions: Long-term follow-up on SBRT for STS found acceptable control and toxicity rates, and warrants further evaluation.

Associated data

ClinicalTrials.gov/NCT02706171